Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Werewolf Therapeutics, Inc. (HOWL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors&#59; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 -"
05/11/2023 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors&#59; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 -"
03/23/2023 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors-"
03/22/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Amended and Restated Loan and Security Agreement, by and between the Company and Pacific Western Bank",
"First Amendment to Amended and Restated Loan and Security Agreement, by and between the Company and Pacific Western Bank"
01/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/10/2022 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Dosed first patient in Phase 1/1b study evaluating WTX-124 as a monotherapy and in combination with KEYTRUDA® in advanced solid tumors&#59; initial data anticipated in the fourth quarter of 2023 -"
09/07/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from Deloitte & Touche LLP",
"Letter from Deloitte & Touche LLP"
08/11/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights - Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613&#59; received $15.0M upfront payment and eligibility for up to $1.26B in downstream milestones as well as royalties on potential future sales -"
04/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amended and Restated Loan and Security Agreement, by and between the Registrant and Pacific Western Bank",
"Amended and Restated Loan and Security Agreement, by and between the Registrant and Pacific Western Bank"
04/07/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/24/2022 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights -Closed upsized IPO in May 2021 raising $120 million in gross proceeds-"
11/10/2021 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program-"
10/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/12/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy